IL-13 inhibitor lebrikizumab
Last Updated: 2026-09-24
Author(s): -
Reviewer(s): -
Cite
Permalink
Ebglyss®
Lilly
Selective monoclonal antibody against IL-13 and inhibition of the heterodimeric receptor signalling complex comprising IL-13Rα1 and IL-4Rα.
Not yet authorised in Switzerland.
No
Not yet authorised in Switzerland.
Solution for subcutaneous injection.
Differential blood count, liver function tests, CRP, pregnancy test, screening for HBV, HCV, HIV and TB (optional: including chest X-ray). Patient training prior to using auto-injectors; first dose administered under medical supervision.
Complete blood count, CRP, pregnancy test every 3 months.
Every 3 months
s.c.
The dosing regimens in clinical trials include single doses of 125 mg, single doses of 250 mg, 125 mg every four weeks, 250 mg every four weeks and 250 mg every two weeks.
Onset of action after 2–6 weeks.
Consider discontinuing treatment if no improvement is seen after 16 weeks.
Patients with chronic inflammatory bowel disease, patients with chronic and/or active severe infections, hypersensitivity to the active ingredients, no data on safety and efficacy in patients with liver dysfunction, no live vaccines.
Approx. 20,000
Insufficient data
Insufficient data
Insufficient data
Hypersensitivity to the active substance or to any of the other ingredients; active, severe infections.
Pregnancy and breast-feeding (a careful risk-benefit assessment is recommended).
Skin infections, herpes virus infections, reactions at the injection site, fatigue.
Insufficient data
Insufficient data
Insufficient data
Insufficient data
Insufficient data
Insufficient data
Insufficient data
This website uses cookies!
We use cookies to tailor our content to your needs and continuously improve our website. You can decide which cookies you want to allow. Detailed information about the cookies we use can be found in our Privacy Policy and Cookie Settings. You can withdraw your consent at any time.
